Department of Biochemistry and Molecular Pharmacology; Schiffer Lab
Immunology of Infectious Disease | Immunotherapy | Infectious Disease | Medicinal-Pharmaceutical Chemistry | Microbiology | Pharmaceutics and Drug Design | Therapeutics | Virus Diseases
The NIH Virtual SARS-CoV-2 Antiviral Summit, held on November 6, 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for COVID-19, including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss SARS-CoV-2 targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.
SARS-CoV-2, antiviral therapeutics, emerging modalities, preclinical, proteases, viral replication machinery
Rights and Permissions
This article is a work of the United States government. Such works are not entitled to domestic copyright protection under U.S. law and are therefore in the public domain.
DOI of Published Version
Hall MD, Anderson JM, Anderson A, Baker D, Bradner J, Brimacombe KR, Campbell EA, Corbett KS, Carter K, Cherry S, Chiang L, Cihlar T, de Wit E, Denison M, Disney M, Fletcher CV, Ford-Scheimer SL, Götte M, Grossman AC, Hayden FG, Hazuda DJ, Lanteri CA, Marston H, Mesecar AD, Moore S, Nwankwo JO, O'Rear J, Painter G, Saikatendu KS, Schiffer CA, Sheahan TP, Shi PY, Smyth HD, Sofia MJ, Weetall M, Weller SK, Whitley R, Fauci AS, Austin CP, Collins FS, Conley AJ, Davis MI. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit. J Infect Dis. 2021 Jun 10:jiab305. doi: 10.1093/infdis/jiab305. Epub ahead of print. PMID: 34111271. Link to article on publisher's site
The Journal of infectious diseases
Hall MD, Anderson JM, Schiffer CA, Conley AJ, Davis MI. (2021). Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit. COVID-19 Publications by UMass Chan Authors. https://doi.org/10.1093/infdis/jiab305. Retrieved from https://escholarship.umassmed.edu/covid19/252
Immunology of Infectious Disease Commons, Immunotherapy Commons, Infectious Disease Commons, Medicinal-Pharmaceutical Chemistry Commons, Microbiology Commons, Pharmaceutics and Drug Design Commons, Therapeutics Commons, Virus Diseases Commons